Stay updated on ABP 798 vs. Rituximab in RA Clinical Trial
Sign up to get notified when there's something new on the ABP 798 vs. Rituximab in RA Clinical Trial page.

Latest updates to the ABP 798 vs. Rituximab in RA Clinical Trial page
- Check2 days agoChange DetectedThe Locations section was updated with many new sites across the US and internationally (examples include Alabama, California, Sofia, Harjuma, Hesse, Saxony-Anhalt). Several previously listed locations were removed.SummaryDifference2%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedA note was added clarifying that PubMed publications are automatically filled and may not all pertain to the study, and the page revision label was updated to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check38 days agoChange DetectedRemoved the site-wide banner about government funding and operating status; the study page content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check52 days agoChange DetectedThe new screenshot shows only layout and UI adjustments with no changes to core trial details such as study design, eligibility criteria, primary/secondary outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check80 days agoChange DetectedUpdated page now communicates government funding lapse impacts and current NIH Clinical Center operating status, and records a new software version (v3.2.0) while removing the old version reference (v3.1.0).SummaryDifference2%

- Check88 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.0%

Stay in the know with updates to ABP 798 vs. Rituximab in RA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABP 798 vs. Rituximab in RA Clinical Trial page.